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Abstract
Protein therapeutics have emerged as a significant role in treatment of a broad spectrum of 
diseases, including cancer, metabolic disorders and autoimmune diseases. The efficacy of protein 
therapeutics, however, is limited by their instability, immunogenicity and short half-life. In order 
to overcome these barriers, tremendous efforts have recently been made in developing controlled 
protein delivery systems. Stimuli-triggered release is an appealing and promising approach for 
protein delivery and has made protein delivery with both spatiotemporal- and dosage-controlled 
manners possible. This review surveys recent advances in controlled protein delivery of proteins 
or peptides using stimuli-responsive nanomaterials. Strategies utilizing both physiological and 
external stimuli are introduced and discussed.
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1. Introduction
Proteins, the “engines of life”, play the most dynamic and diverse roles among all the 
macromolecules in human body, including catalyzing biochemistry reactions, controlling 
cell fates, forming cellular structures, providing tissue scaffolds, and transporting molecules 
[1]. The history of protein therapeutics usage can be traced back to 1922, when insulin was 
first purified from bovine pancreas and served as a life-saving daily injection for type 1 
diabetes treatment [2]. However, protein therapeutics remained rarely used until the 
emergence of the first FDA approved recombinant protein therapeutic human insulin 32 
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years ago [3]. Ever since then, the development of protein therapeutics has experienced an 
explosive growth and protein drugs now play a pivotal role for treating a broad range of 
diseases, covering cancer, metabolic disorders and autoimmune diseases. To date, more than 
130 proteins or peptides have been approved for clinical use by FDA [1]. Compared with 
small-molecule drugs, protein therapeutics possess several advantages attributed to their 
highly specific and complex set of functions and superior biocompatibility [1]. Protein 
therapeutics can also bypass the requirement of permanent or random changes to genetic 
makeup of the cell, and is therefore a safer alternative compared with gene therapy [4].
Although the last few decades have witnessed significant progresses in the development of 
protein therapeutics, several challenges still remain to be addressed. Direct delivery of 
protein therapeutics suffers from their in vitro and in vivo instability, immunogenicity and a 
relatively short half-life within the body [5]. Also, most proteins are negatively charged at 
neutral pH, resulting in poor membrane permeability for intracellular delivery [6-8]. 
Therefore, vast efforts have been put into the design of versatile protein delivery systems for 
enhancing stability of cargoes, achieving “on demand” precise release and enhancing 
therapeutic efficacy [9]. In light of this, delivery approaches based on stimuli-responsive 
smart materials have drawn extensive attentions these years [10]. Stimuli-responsive design 
is capable of conformational and chemical changes in response to environmental stimuli, 
and these changes are subsequently accompanied by variations in their physical properties 
[11]. Such action can not only facilitate release of drug with desirable pharmacokinetics, but 
also guarantee that drug can be spatiotemporally released at a targeting site. As summarized 
using a “magic cube” in Fig. 1, based on the distinct functions of target proteins, specific 
nanomaterials and formulations were engineered and tailed with integration of stimuli 
triggers. As the central component of a design, stimuli can be typically classified into two 
groups, including physiological stimuli such as pH, redox potential, enzymatic activities and 
glucose concentration and external stimuli such as temperature, light, electric field, magnetic 
field and mechanical force [12]. Other three “faces” of the “magic cube” could involve a 
variety of diseases, specific targeting sites and bio-inspired designs. We will also 
incorporate these elements during our discussion.
The emphasis of this review is to introduce and classify recent progress in the development 
of protein/peptide delivery systems via nano-scale formulations integrated with stimuli-
responsive moieties. We will survey representative examples of each stimulus type. 
Advantages and limitations of different strategies, as well as the future opportunities and 
challenges will also be discussed.
2. Physiological stimuli-triggered delivery
2.1. pH-sensitive nanosystems
Physiological pH gradients have been widely utilized in the design of stimuli-responsive 
nanosystems for controlled drug delivery to target locations, including specific organs, 
intracellular compartments or micro-environments associated with certain pathological 
situations, such as cancer and inflammation [9]. These delivery systems are typically based 
on nanostructures that are capable of physical and chemical changes on receiving a pH 
signal, such as swelling, charge conversion, membrane fusion and disruption and bond 
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cleavage [13]. There are two general strategies to make such pH-responsive nanomaterials. 
One strategy is to utilize the protonation of copolymers with ionizable groups [14, 15]. The 
other strategy is to incorporate acid-cleavable bonds. [16-20]. Adopting these two 
fundamental mechanisms, researchers have developed numerous pH-responsive 
nanomaterials to achieve controlled delivery of protein/peptide therapeutics at both cellular 
and organ level [21]. At cellular level, pH-responsive nanomaterials have been designed to 
escape acidic endo-lysosomal compartments and lead to cytoplasmic drug release [22, 23]. 
At organ level, pH-responsive oral delivery systems for controlled delivery of proteins and 
peptides have been developed for differential drug uptake along the gastrointestinal tract 
[24, 25]. Herein, we will introduce recently developed approaches for intracellular delivery 
and oral delivery. The relevant systems covered in this manuscript are summarized in Table 
1.
2.1.1. pH-responsive nanosystems for intracellular protein/peptide delivery—
After endocytosis, rapid endosomal acidification occurs due to a vacuolar proton ATPase-
mediated proton influx [26]. As a result, the pH levels of early endosomes, sorting 
endosomes, and multivesicular bodies drop rapidly to pH<6.0 [27]. The process of 
endosomal acidification can be harmful to the cargo molecules, especially macromolecules 
such as DNA, small interfering RNA (siRNA) and proteins. However, endosomal 
acidification can also be used as a trigger for endosomal escape and cargo release. As the 
most studied stimuli-responsive mechanism, pH-triggered intracellular drug release has been 
extensively investigated and applied in the development of intracellular protein delivery 
system. pH-responsive protein/peptide delivery systems utilizing various formulations 
including micelles, liposomes, polymersomes, protein nanocapsules and inorganic 
nanoparticles such as mesoporous silica nanoparticles (MSNs) have been developed.
Utilizing the above mentioned pH reduction, Kataoka and co-workers developed an 
intracellular protein delivery strategy based on charge-conversional polyionic complex (PIC) 
micelles [28, 29]. The core-shell structured nanomicelles were prepared via electrostatic 
interactions between diblock copolymers, which were endued with both a neutral 
poly(ethylene glycol) (PEG) block and an ionic poly(amino acid) block, and their 
counterions. Equine heart cytochrome c (CytC), a cationic protein, was reversible 
conjugated with citraconic anhydride and cis-aconitic anhydride to increase charge density 
and eventually invert surface charge. The modified CytC was then mixed with a cationic 
block copolymer, PEG–poly[N-{N’-(2-aminoethyl)-2-aminoethyl}aspartamide] (PEG–
pAsp(DET)) to form PIC micelles. The PIC micelles remained stable at physiological pH 
(pH 7.4), while rapidly disintegrated at pH 5.5 based on a charge-conversional principle. 
Controlled endosomal release of CytC was confirmed in human hepatoma cell line (HuH-7). 
The researchers continued to apply this system to deliver bioactive immunoglobulin G 
(IgG), antibody with superior selectivity towards its corresponding antigen, into the 
cytoplasm of HuH-7, demonstrated the potential of this delivery strategy for intracellular 
imaging and controlled delivery.
Liechty et al. demonstrated the ability of a pH-sensitive phenylalanine derivatized polymer 
to deliver Apoptin protein into mammalian cells [30]. In this design, hydrophobic L-
phenylalanine were grafted onto the carboxylic acid moieties along the backbone of poly(L-
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lysine iso-phthalamide) with a stoichiometric substitution degree of 75 mol% (designated as 
PP-75). [31] The resulted polymer with both hydrophobic side chains and ionisable carboxyl 
groups would experience conformational change from extended state to collapsed globular 
state upon pH reduction (decreased to below its pKa). Apoptin, the cargo protein, was used 
in the form of a fusion protein with maltose binding protein (MBP) to enhance solubility. 
Evidenced by the results of flow-cytometry experiments and mean fluorescence, both the 
proportion of cells with internalized PP-75-FITC and amount of internalized PP-75-FITC 
increased with polymer concentration. In vitro, MBP-Apoptin spontaneously forms soluble, 
non-covalent, globular complexes with an approximate 80 nm diameter. Attributed to the N-
terminal portion of Apoptin and stabilized by hydrophobic interactions, these complexes 
were composed of 30~40 MBP-Apoptin subunits, and had estimated molecular weight of 
approximately 2.5±0.3 MDa. The ability of PP-75 to facilitate delivery of fluorescent MBP-
Apoptin conjugated with Alexa Fluor 647 (MA-AF647) to Saos-2 cells was examined via 
flow-cytometry. Complex dissociation is likely due to intercalation and solubilization of 
multimeric MBP-Apoptin globules by PP-75, enabling the migration of individual MBP-
Apoptin subunits through the gel. Preliminary research has been conducted to confirm MBP-
Apoptin activity delivered by PP-75. When MBP-Apoptin and PP-75 were delivered in vivo 
to Saos-2 cells, flow-cytometry analysis showed an approximately 30% increase of cell 
population in the mid-apoptotic state, as compared to either MBP-Apoptin or PP-75 alone. 
Hu et al. utilized pH-responsive cross-linked PDEAEMA-core/PAEMA-shell particles for 
intracellular delivery of membrane-impermeable macromolecules, including ova protein, 
influenza A, and siRNA [32]. These particles were designed to physically segregate the 
function of cell/drug binding mediated by the particle shell from the function of 
endolysosomal disruption mediated by the core. Cationic particles with a shell containing 
primary amines and a core composed of cross-linked poly (diethylaminoethyl methacrylate) 
(PDEAEMA) were shown to elicit highly efficient endolysosomal disruption via the “proton 
sponge” effect while exhibiting minimal cytotoxicity. In their studies, Hu et al. 
demonstrated that proteins with net negative charge could be adsorbed to the cationic shell 
of pH-responsive core-shell particles, allowing cross-presentation to antigen-specific CD8+ 
T-cells. Cytosolic delivery of protein antigens by these materials dramatically lowered the 
dose of antigen required to elicit naïve CD8+ T-cell priming by DCs by at least ~100-fold 
compared to soluble antigen uptaken by DCs.
Giannotti and co-workers reported the synthesis of functional trimethyl chitosan (TMC)-
based polyelectrolyte complex (PEC) nanocarriers for the lysosomal enzyme R-GAL and 
prepared the assembly via simple aqueous solution mixing and ionotropic gelation [33]. 
According to atomic force microscopy (AFM) results, these polyelectrolyte nanoparticles 
were stable and active under physiological conditions and able to release the loaded 
enzymes at acidic pH. Gu et al. utilized layer-by-layer assembly of PADH (tertiary amine 
and hydrazide grafted polyaspartamide) and PACA (carboxyl and aldehyde grafted 
polyaspartamide) on silica spheres to prepare biodegradable shell cross-linked nanocapsules 
for protein delivery [14]. Both of the polyaspartamide derivatives are protein-like structured 
polymers obtained by aminolysis reaction of polysuccinimide which are water-soluble and 
biodegradable. Bovine serum albumin (BSA) was used as a model protein, and BSA 
encapsulated nanocapsules were prepared through a three-step procedure: i) layer-by-layer 
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assembly of PADH and PACA on the surface of protein-entrapped amino-functionalized 
silica spheres; ii) hydrazone cross-linking and iii) removal of silica core. BSA release 
exhibited a pH-dependent behavior: BSA release rate increased significantly as the ambient 
pH dropped from the physiological pH to acidic pH. Further cell viability study 
demonstrated that the shell cross-linked nanocapsules exhibited good biocompatibility.
Another facile yet delicate approach to achieve controlled protein release upon pH trigger is 
to utilize the cargo protein itself as a vehicle. Yan and co-workers reported an intracellular 
protein delivery system based on a nanocapsule with a single-protein core and a thin 
permeable polymeric shell (Fig. 2) [34]. Simply put, they covalently linked polymerizable 
vinyl groups to the protein core. And each protein core was wrapped in a thin polymer shell 
via subsequent polymerization in an aqueous solution containing monomers and 
crosslinkers. The degradability of the polymer shell was a result of the degradable 
crosslinkers, and the surface charge of the nanocapsule could be precisely regulated via 
tuning the ratio of the monomers (cationic monomers versus neutral monomers). The as-
prepared nanocapsules displayed a positive surface charge, which was desirable for cellular 
uptake. A notable advantage of this approach is that the single-protein core here can be 
chosen from a vast library of proteins, thus, this platform offers a general approach for the 
controlled delivery of a wide range of proteins. In this specific study, the researchers 
demonstrated successful delivery of enhanced green fluorescent protein (EGFP), horseradish 
peroxidase (HRP), BSA, superoxide dismutase (SOD) and caspase-3 (CAS). The researchers 
further developed this design principle and applied it in the synthesis of a triple-enzyme 
nanocomplex via DNA-directed assembly and nano-encapsulation [35]. The synthesis of this 
triple-enzyme nanocomplex was achieved by adopting a three step procedure. A DNA-
inhibitor scaffold linked with three inhibitors specific for the three enzymes was first 
formed, and the construction of triple-enzyme complex was realized based on the specific 
binding between the enzymes and the inhibitors. A polymer shell was then formed via in situ 
polymerization and the DNA-inhibitor scaffold was removed. Utilizing this approach, the 
researchers achieved controlled delivery of alcohol oxidase and catalase in order to reduce 
blood alcohol levels, which displayed potential as an alternative antidote and prophylactic 
for alcohol intoxication.
MSNs are appealing carriers for delivery of various biomolecules due to their excellent 
biocompatibility and stability [36]. Compared with other controlled protein delivery 
systems, using MSNs as intracellular protein delivery carriers has several superiorities: i) 
High protein-loading capacity can be achieved with the large pore volumes (>1 cm3/g) of 
MSNs. ii) The chemically and mechanically stable inorganic oxide framework of MSNs 
protects the cargo protein from exposure to harmful species. iii) It has been previously 
proved that MSNs are capable of escaping endolysosomal entrapment. MSNs functionalized 
with hydrophobic or acid labile moieties were recently employed to transport proteins into 
cells [37]. Wu et al. prepared aldehyde-displaying silica nanoparticles (MSN-aldehyde) 
containing lysosome activatable rhodamine-lactams for controlled protein delivery via 
lysosomal acidity-triggered release [38]. The MSN-aldehyde nanocomposites were site-
specifically embodied into lysosomes of HepG2, HeLa and L929 cells where the loaded 
protein cargoes, including arginase and green fluorescent protein, were released through 
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lysosomal acidity-mediated hydrolysis of the imine cross-linkages. The released proteins 
escaped from lysosomes into cytosol where arginase efficiently induced autophagy of the 
host cells. Slowing and co-workers synthesized and characterized a MCM-41-type MSN 
material with a large pore diameter (5.4 nm) [39]. Cell-membrane-impermeable protein 
cytochrome c was loaded as a model protein and its uptake and release profiles were 
investigated. The enzymatic activity of the pore-released protein was analyzed and 
compared with that of the native cytochrome c in physiological buffer solutions in order to 
examine any possible harmful effects caused by encapsulation. The test results showed 
identical kinetics of the two enzyme-catalyzed reactions, indicating the practicality of this 
MCM-41-type MSN material in intracellular protein delivery.
2.1.2. pH-responsive nanosystems for oral protein/peptide delivery—Each 
segment of the gastrointestinal tract maintains its own characteristic pH level, from the 
acidic stomach lumen (pH 1-3) for digestion [40], to the alkaline duodenum and ileum (pH 
6.6-7.5) for the neutralization of chyme [41, 42]. Oral delivery is an attractive drug delivery 
route for its convenience and patient compliance. However, orally-delivered drugs are 
exposed to strong gastric acid and presystemic enzymatic degradation, resulting in poor 
systemic exposure. Efficient oral delivery of proteins and peptides are hindered by three 
major barriers, including the enzymatic barrier, the mucus gel layer barrier and the 
absorption barrier. The development of smart oral delivery carriers capable of protecting 
cargo protein from digestion while releasing the loaded proteins at target site is therefore 
highly desirable.
Gao et al. developed a biodegradable and pH-sensitive hydrogels composed of four types of 
pH-sensitive polyacrylic acid derivatives (PAAD) and a biodegradable poly(L-glutamic 
acid) (PGA) crosslinker for oral delivery of proteins and peptides [43]. In this work, insulin 
was loaded into the hydrogels as a model protein. The results of the investigations of 
swelling and biodegradation behaviors indicated that the hydrogels based on PAAD with 
higher hydrophobicity exhibited the lower swelling ratios and less biodegradation in the 
condition of mimicking stomach environment, while the hydrogels showed the higher 
swelling ratios and more biodegradation in the condition of mimicking intestine 
environment. Following oral administration of insulin-loaded hydrogels to streptozotocin-
induced diabetic rats, significantly hypoglycemic effect was observed within 7 h. Lin and 
co-workers synthesized pH-responsive nanoparticles (NPs) composed of chitosan (CS) and 
poly-γ-glutamic acid (γ-PGA) blended with tripolyphosphate (TPP) and MgSO4 (multi-ion-
crosslinked NPs) and investigated their effectiveness in oral delivery of insulin [44]. The 
NPs were used to encapsulate insulin when pH<6 and release it at higher pH by the 
deprotonization of chitosan and destabilization of NPs.
Oral delivery using nanoparticles is often highly limited by their low transportation 
efficiency across the intestinal epithelium. In order to address this, Pridgen and co-workers 
developed Fc-targeted nanoparticles and evaluated their potential in oral delivery of insulin 
[45]. The surface of PLA-PEG NP was modified with IgG Fc fragments to target the 
neonatal Fc receptor (FcRn), which played an essential role in the transport of IgG across 
epithelial barriers. Under the acidic environment of the intestine, IgG Fc on the NP surface 
bond to FcRn on the apical side of epithelial cells. Fc modified NPs then went across the 
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epithelial cell through the FcRn transcytosis pathway. Upon exocytosis, Fc modified NPs 
dissociated from FcRn under physiological pH, the NPs were thus set free and eventually 
entered systemic circulation. In this study, enhanced transepithelial transportation was 
observed both in vitro and in vivo.
2.2. Redox-responsive nanosystems
Glutathione (GSH) is a tripeptide found at 2 to 3 orders higher level (approximately 2-10 
mM) in the cytosol than the extracellular fluids (approximately 2-20 μM) [46], rendering the 
relatively low intracellular redox potential. Thus, redox-responsive vehicles are mostly 
intended to disassemble and release drugs in the cytosol. Disulfides are degradable in 
presence of various reducing agents, including GSH, while the resulting thiol groups can 
reversibly reform disulfide bonds upon oxidation. [47] This thiol-disulfide exchange offers 
opportunity to achieve programmable drug release utilizing redox potential as trigger. [48] 
Attributed to the reversible characteristic of thiol-disulfide chemistry, disulfide bonds can be 
incorporated into either the polymer backbone or the crosslinkers in order to design redox-
responsive nanomaterials.
Zhao et al. reported the preparation of redox-responsive single-protein nanocapsules for 
intracellular protein delivery [49]. In this delivery system, target protein was non-covalently 
encapsulated into a positively-charged polymeric shell interconnected by disulfide-
containing crosslinkers via in situ interfacial polymerization. Cell-free assays were 
conducted to demonstrate the dissociation of the polymeric shell under reducing conditions 
and subsequent release of protein in the presence of GSH. The nanocapsules were proved to 
be capable of validly releasing protein cargoes into cytosol. Caspase 3 (CP-3) was delivered 
and hence induced apoptosis in a variety of human cancer cell lines, including HeLa, MCF-7 
and U-87 MG, using these nanocapsules as carriers. Recently, Zhao and co-workers 
continued to report a core-shell structured redox-responsive polymeric protein nanocapsule 
for intracellular delivery of recombinant maltose-bindingprotein fused apoptin (MBP-APO) 
(Fig. 3) [50]. In this delivery system, MBP-APO was reversibly encapsulated in a positively 
charged, water soluble polymer shell and was released in the reducing environments of 
cytoplasm.
Zheng et al. designed and synthesized biodegradable redox-responsive nanocapsules 
adopting the layer-by-layer technique with poly (L-aspartic acid) and chitosan as vehicles 
for transmucosal delivery of proteins and peptides [51]. TEM images showed that intact 
nanocapsules were obtained and the shell of the nanocapsules was about 40 nm. Muco-
adhesion test indicated that the adsorption amount of the mucin could reach up to 96.2 μg 
per 2 mg. The cell viability test demonstrated that all types of nanocapsules had good 
cytocompatibility and the cell viability was above 90%. As a model protein, insulin was 
loaded into the nanocapsules, and with a loading efficiency about 5%. The release amount of 
insulin could be regulated by the levels of GSH.
2.3. Enzyme-responsive nanosystems
Enzymes play a central role in biochemical processes, and therefore are important targets for 
drug development [52]. When an enzymatic activity is associated with a particular tissue or 
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an enzyme level is upregulated at the target site, nanomaterials can be designed to deliver 
drugs via specific enzymatic conversion. Compared with delivery approaches utilizing other 
internal or external stimuli, such as temperature, pH, and light, the enzyme-based approach 
represents an elegant biocompatible method of both high sensitivity and selectivity for 
programmed delivery of proteins to the enzyme-overexpression target sites [53], which has 
led to growing interest in developing enzyme-responsive nanomaterials as smart protein 
delivery systems. In the past few years, considerable progresses have been made in the field 
of enzyme-responsive protein delivery systems.
Biswas et al. designed a biomimetic protein delivery system, where cargo proteins were 
encapsulated in a nano matrix crosslinked by bisacrylated peptides with a specific sensitivity 
towards furin [54]. The development of this furin-degradable construction was inspired by 
the various and essential natural rules of furin, a ubiquitous intracellular protease expressed 
in all eukaryotic organisms and many mammalian cells. Furin is a transmembrane protein 
cycling between the surface and the trans Golgi network during substrate processing. [55] 
Elevated furin expression is associated with a series of diseases, including cancer, thus can 
be utilized as a target for drug delivery towards various cell lines, especially cancerous cell 
lines. A general mechanism adopting a facile two-step procedure was developed for the 
delivery of a wide sort of functional proteins: positively charged monomer (N-(3-
aminopropyl) methacrylamide (APMAAm)), neutral monomer (acrylaminde (AAM)), and 
furin-cleavable bisacrylated peptide crosslinkers were first enriched around protein surfaces 
via electrostatic and hydrogen bonding interactions, followed by the formation of a thin 
polymer layer around protein surfaces through in-situ free-radical polymerization, leading to 
the formation of protein nanocapsules (NCs) with controlled composition. The surface 
charge of the nanocapsule was controlled via regulating the ratio of the positive-charged and 
the neutral monomers. The sizes of resulting protein-containing NCs were within the range 
of 10 to 15 nm. And these NCs were positively charged, favorable for intracellular uptake. 
Furin-triggered protein release from the NCs was quantified via the enzyme-linked 
immunosorbant assay (ELISA) using enhanced green fluorescence protein (eGFP) as a 
model protein. No significant protein release was observed over 24 h in absence of furin, 
conversely, upon the addition of 4 unit furin, a rapid release of eGFP was observed and 
~80% of the encapsulated eGFP was released before reaching the plateau level. Utilizing 
this nanoplatform, the researcher delivered both cytosolic and nuclear proteins, such as 
EGFP, CP3, BSA and the transcription factor Klf4, in active forms to different of cell lines. 
Wen et al. reported an enzyme-responsive delivery platform with controlled-releasing 
capability and specificity based on protein nanocapsules [56]. When exposed to proteases, 
the peptide crosslinkers surrounding the protein surface were cleaved, releasing their protein 
cargo. Specific enzyme-degradation of nanocapsules could be achieved by picking particular 
enzymes and utilizing peptide crosslinkers with specific sequences. In their research, 
vascular endothelial growth factor (VEGF) for promoting angiogenesis was used as a model 
protein [57]. Since matrix metalloproteinases (MMP) [58] and serine proteases, such as 
plasmin, are generally upregulated in diseased or injured tissues [59, 60], they were chosen 
as the enzyme trigger to demonstrate the controlled release of VEGF from their 
nanocapsules.
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Aimetti et al. presented a method of fabricating enzyme-responsive PEG hydrogels for 
controlled protein delivery via thiol-ene photopolymerization [61]. Thiol-ene 
photopolymerization is based on the radical catalyzed addition of a thiol to a vinyl 
functional group. At the presence of light, a photoinitiator abstracts a hydrogen atom from a 
thiol and form a thiyl radical which can add across a carbon-carbon double bond. The 
subsequent propagation-chain transfer events result in a step-growth mechanism. Based on 
this mechanism, highly cross-linked polymer networks are formed when multifunctional 
monomers with an average functionality greater than two are utilized [61, 62]. In order to 
treat inflammation locally, they designed a PEG hydrogel system with human neutrophil 
elastase (HNE) sensitive peptide crosslinkers synthesized via thiol-ene photopolymerization 
rendering the gel degradable at sites of inflammation. Protein therapeutics physically 
entrapped within the network would be selectively released upon exposure to HNE. The 
controlled delivery of a model protein, BSA, based on this PEG hydrogel system was 
demonstrated. Thornton and co-workers functionalized Amino-functionalized poly (ethylene 
glycol acrylamide) (PEGA) hydrogel particles with peptide actuators that cause charge-
induced swelling and cargo release upon exposure to enzyme stimuli [63]. The peptide 
actuators here were designed based on both the specificity of the target enzyme and the 
charge properties of the to-be released protein cargo, thereby allowing for tunable release 
profiles. Fluorescently labelled albumin, avidin and proteins of similar size but opposite 
charge were released at a rate that was regulated by the peptide actuator linked to the 
polymer carrier, exhibiting a highly controlled release mechanism. In this work, release 
profiles were examined using a combination of fluorescence spectroscopy of the solution 
and two-photon fluorescence microscopy in order to analyze enzymatically triggered 
molecular events within hydrogels during the initial stages of protein release.
Jiang et al. recently reported an enzyme-responsive gel-liposome-mediated delivery system 
and achieved programmed co-delivery of tumor necrosis factor-related apoptosis inducing 
ligand (TRAIL) and small-molecule anticancer drug Dox (Fig. 4) [64]. The core-shell 
structured nano-vehicle was designed to have a cell-penetrating peptide (CPP, R8H3) 
modified liposome (R8H3-L) core for Dox loading and a hyaluronic acid (HA) based cross-
linked shell for protein encapsulation (designated Gelipo). This smart controlled drug 
delivery system underwent sequential trigger-responsive mechanisms in the tumor 
microenvironment, leading to precise release of protein and small-molecule cargoes at 
different target sites. First, hyaluronidase (HAase), which was proved to be highly expressed 
in tumor area, promoted the degradation of the HA shell and released the encapsulated 
TRAIL, which then bond to the plasma membrane and induced apoptosis. The exposed inner 
core subsequently entered tumor cell and located into endo-lysosomes. Consequent Dox 
release was then achieved with the aid of R8H3. The synergistic antitumor efficacy of 
TRAIL/Dox-Gelipo was thoroughly evaluated with both in vivo and in vitro assays. HAase-
treated TRAIL/Dox-Gelipo, with concentration ratio fixed at 2 ng/mL TRAIL and 100 
ng/mL Dox, induced a higher than 80% apoptosis ratio on MDA-MB-231 cells, which was 
prominent compared with the 36.48% of free TRAIL (2 ng/mL) and 38.52% of Dox-R8H3-
L (100 ng/mL). The researchers then investigated the in vivo antitumor efficacy of TRAIL/
Dox-Gelipo using MDA-MB-231 tumor-xenograft mouse models. The Dox amount in 
tumor tissues was increased by 5.72- and 2.70-fold, respectively, using Gelipo as carrier 
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instead of Dox solution and Dox-R8H3-L. Also, a notable enhanced effect on tumor 
inhibition was observed after TRAIL/Dox-Gelipo treatment.
2.4. Glucose-responsive insulin release
Diabetes is a disorder of glucose regulation, which is performed by an accumulating of 
blood glucose [65]. According to data from International Diabetes Federation, in 2013, there 
are 382 million children and adults throughout the world suffering from diabetes, and by 
2035, this number will rise to 592 million [66]. It has become one of the top health concerns 
of our time. So far, the major treatment of this disease has been insulin injection together 
with diet restriction, which is both inconvenient and painful, resulting in a huge desire for an 
alternative treatment which can directly response to blood glucose levels and achieve a 
noninvasive and continued insulin administration [67]. Therefore, glucose-responsive based 
closed-loop platforms have attracted more and more attention in the recent decades. Three 
typical strategies have been developed for glucose-responsive insulin delivery systems 
(GRIDS) [68]: incorporation of glucose oxidase (GOx), glucose-binding proteins and 
boronic acids as glucose-sensitive moieties. We will briefly analyze some recently 
developed GRIDS.
2.4.1 Glucose oxidase based Insulin delivery—GRIDS based on GOx are one of the 
most studied glucose-responsive systems that have been thoroughly explored in the past few 
decades. These GRIDS are typically prepared via the combination of GOx and pH-
responsive hydrogel backbones. GOx converts glucose into gluconic acid in the presence of 
oxygen, resulting in a decrease of pH, which triggers the swelling or deswelling behavior of 
the pH-sensitive backbones, contributing to the controlled release of insulin. In 2002, 
Guiseppi-Elie et al. reported a glucose-triggered insulin delivery system based on hydrogels 
containing GOx and insulin [69]. GOx was entrapped inside the network of the amphiphilic, 
pH-responsive membranes (synthesized via the copolymerization of hydroxyethyl 
methacrylate, dimethylaminoethyl methacrylate and 3-trimethoysilypropyl methacrylate) via 
UV polymerization, contributing to the glucose-responsiveness of the system. Insulin 
loading was achieved via either gel entrapment or equilibrium partitioning.
Gu et al. developed a novel glucose-triggered release strategy for the self-regulated insulin 
delivery via an injectable and acid-degradable polymeric network (Fig. 5) [70]. In this work, 
surface-modified dextran (designated m-dextran) was utilized as an acid-degradable and 
biocompatible matrix material. Dextran nanoparticles coated with chitosan (positively 
charged) and alginate (negatively charged) were prepared adopting double emulsion method, 
respectively. The cohesive gel-like nano-network here was formed via electrostatic 
interaction between oppositely charged dextran nanoparticles loaded with insulin and GOx. 
In the hyperglycemic state, this porous architecture would dissociate and subsequently lead 
to the release of insulin as a result of the catalytic conversion of glucose into gluconic acid. 
Based on in vitro studies, pulsatile insulin release was achieved in response to glucose 
concentrations. The researchers then extended their investigations to in vivo systems by 
applying this degradable nano-network in type 1 diabetic mice. According to the in vivo 
studies, a single injection of this reported nano-network was able to stabilize blood glucose 
levels within the normoglycemic state for up to 10 days. This novel insulin delivery nano-
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network based on glucose oxidase has showed a great potential in the development of smart 
insulin delivery systems and is a promising strategy in self-regulated and long-term diabetes 
therapy. Gu et al. also developed an injectable glucose-responsive system based on enzyme 
nanocapsule-integrated pH-responsive microgels [71]. This glucose-responsive insulin 
delivery platform, prepared via a facile one-step electrospray procedure, was composed of a 
pH-responsive chitosan matrix, enzyme nanocapsules, and recombinant human insulin. 
Upon being exposed to hyperglycemic environment, GOx encapsulated in nanoparticles 
began to converting glucose into gluconic acid, which caused the protonation of the chitosan 
network, and eventually led to the swelling of the microgel. This system was then further 
adjusted to achieve different insulin release rates under different blood sugar concentrations. 
In vivo studies carried out in streptozotocin-induced diabetic mice demonstrated the 
possibility of using this smart system in glucose regulation for diabetes therapy.
2.4.2 Glucose-binding proteins based insulin delivery—There are three major 
classes of glucose-binding proteins (apo-enzymes, lectins and a family of proteins recently 
found in certain bacteria), among which lectins are most used in the development of GRIDS. 
Lectins are sugar-binding proteins which are highly specific due to their sugar moieties [72]. 
The first lectin that could be purified on a large scale and achieved on a commercial basis 
was concanavalin A (ConA) and the first GRIDS based on ConA was developed by 
Brownlee and Cerami in 1979 [73]. ConA is a saccharide-binding lectin which displays 
reversible affinity for non-reducing α-D-mannose, α-D-glucose, N-acetyl-D-glucosamine and 
polysaccharide with unmodified hydroxyl groups at C-3, C-4, and C-6 [74]. In the native 
state of ConA, one molecule binds two metal atoms: one Ca2+ and one transition metal ion, 
usually Mn2+. The binding site for the sugar is adjacent to the metal atoms. Then, in the 
active state of ConA, four molecules join together to form a functional aggregate with four 
binding sites. Such a specific structure of ConA aggregate is capable of inducing affinity 
gelation of polysaccharide or other polymers that contain glucose moieties. Free glucose can 
seize the specific binding sites of ConA-polymer complex, leading to the dissociation of the 
complex and thus forming glucose-responsive systems [75, 76].
Tanna and co-workers developed a glucose-responsive gel formulation, which contained 
ConA and specific polysaccharides for the controlled delivery of insulin [77]. The gel here 
was synthesized through the covalent coupling to two structurally different carbomers 
(Carbopol 934P and Carbopol 941P) achieved by using the carbodiimide chemistry 
described by Tanna et al. in 2001 [78]. The gel was proved to be glucose-sensitive and could 
be triggered repeatedly by the stimulus of glucose. Their study showed the possibility to 
formulate glucose-responsive gels with covalently coupled carbomer carriers with distinct 
structures. Nie et al. prepared glucose-responsive hydrogels based on methacrylate 
derivatives of dextran and ConA and investigated its capability in self-regulated insulin 
delivery [79]. The results showed that the insulin release was dependent on the glucose 
concentration. The glucose sensitivity, which could be regulated by the degree of 
substitution (DS) of the dextran methacrylate derivative, was reversible. The bioactivity of 
released insulin was also studied, and the results demonstrated that the activity of insulin 
remained unchanged.
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2.4.3 synthetic boronic acids based Insulin delivery—The water-solubility of 
boronic acids can be regulated by pH or diol concentration. In aqueous, boronic acids exist 
in an equilibrium between an undissociated neutral trigonal form and a dissociated anionic 
tetrahedral form. With the existence of saccharides, the anionic form binds with diols 
reversibly to form a 5- or 6-membered ring cyclic boronate ester, shifting the above 
equilibrium towards the anionic form side. This unique behavior of boronic acids can be 
used to design GRIDS.
Kim and co-workers reported a sugar-responsive insulin delivery system based on 
polymersomes of polyboroxole block copolymers [80]. In their study, monosaccharide-
responsive poly(styreneboroxole) (PBOx) was synthesized from the controlled radical 
polymerization of a boroxole-containing styrenic monomer adopting the reversible addition-
fragmentation and chain transfer (RAFT) method. Amphiphilic block copolymers of PBOx, 
which could self-assemble into polymersomes in water, were then prepared by performing a 
RAFT polymerization of PBOx together with a PEG-based macro-chain-transfer agent. 
Polymersomes of these PBOx copolymers could encapsulate water-soluble cargoes such as 
insulin in their water-filled inner compartment [81]. Kim et al. investigated the controlled 
insulin delivery ability of these saccharide-responsive polymersomes by encapsulating 
fluorescein isothiocyanate (FITC)-labeled human insulin within polymersomes and 
successfully demonstrated that sugar-triggered insulin release under physiologically relevant 
pH conditions could be achieved with such a PBOx based polymersome system.
Lin et al. designed and prepared a boronic acid-functionalized MSN-based drug delivery 
system (BA-MSN) in order to achieve the controlled double release of both cyclic adenosine 
monophosphate (cAMP), which could activate Ca2+ channels of pancreas beta cells and thus 
stimulate insulin secretion upon glucose trigger (Fig. 6) [82]. In this delivery model, 
gluconic acid-modified insulin was immobilized onto the exterior surface of MSN and 
served as caps to encapsulate cAMP molecules. Their investigation demonstrated that BA-
MSN could be applied as an efficient co-delivery system for glucose-responsive triggered 
release of insulin and cAMP.
3. External stimuli-triggered delivery
3.1. Thermal stimuli
Thermal sensitive polymers are polymers which exhibit a volume phase transition at a 
certain temperature. Thermal responsive behavior of polymers is generally viewed as a 
phenomenon governed by the balance of hydrophilic and hydrophobic moieties on the 
polymer chain [83]. This temperature-responsive character of certain polymers has been 
often applied in the design of stimuli-responsive delivery systems.
One major class of thermal sensitive materials are temperature-responsive covalently 
crosslinked hydrogels, which are probably the most extensively studied thermal responsive 
drug delivery systems. Although there are several different ways to immobilize proteins in 
gels, the number of these methods which can be adopted in drug delivery systems is rather 
limited. One commonly used strategy is to mix the cargo molecules with proper monomer, 
crosslinker and initiator, which then polymerize and form matrix encapsulated with the 
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cargo molecules. This method can be modified as adding cargo molecules into the formed 
polymer and then crosslinked them chemically. The most used protein loading strategy is to 
utilize the equilibrium swelling of a hydrogel in a protein-containing solution. According to 
the studies of Gehrke et al., high protein-loading efficiency can also be achieved via 
partitioning proteins from polymer solutions of low affinity [84]. Thermal-responsive 
materials are typically materials with properties, such as solubility, displaying a nonlinear 
relationship with temperature. [85] Thermal sensitive materials hold a sharp transition 
temperature at which they either become increasingly soluble or insoluble. [86] Polymers 
become insoluble upon being heated to the transition temperature exhibit a lower critical 
solution temperature (LCST). The local temperature of the tumor microenvironment is 1-2 
°C higher than that of normal tissue, thence thermal responsive polymers will undergo phase 
change from the hydrophilic extended state to hydrophobic collapsed state upon transported 
to tumor site. This temperature-triggered phase switch endues thermal-responsive polymers 
the capability to release drugs when entering tumor sites. Most of the thermal-sensitive 
polymers used in biomedical applications exhibit LCST behavior [87], while only a few 
natural polymers display LCST behavior. Zhang et al. reported a chitosan-PEG copolymer 
based injectable thermo reversible hydrogel for sustained protein release [88]. The hydrogel 
was prepared via grafting PEG onto the chitosan backbone. This thermo responsive system 
was then studied for protein delivery, where BSA was chose as model cargo protein. Their 
study also confirmed that the structure of BSA maintained unchanged after the release. 
Compared with natural polymers, synthetic polymers display more potential in the 
development of thermal responsive protein delivery system. The most extensively studied 
synthetic polymer which displays a thermo responsive character in biomedical applications 
is poly(N-isopropylacrylamide) (PNIPAm), due to the fact that its LCST is 32 °C, therefore 
suitable for in situ gelling [89]. Yang and co-workers studied the interactions between 
proteins and PNIPAAm hydrogels, which were cross-linked using N, N’-
methylenebisacrylamide and displayed a low LCST. Insulin and BSA were chose as model 
proteins in order to examine the ability of PNIPAAm hydrogels as potential protein delivery 
carriers. The release of the protein was not complete as a result of the strong interaction 
between the polymer and the cargo protein [90]. Hu et al. achieved a sufficient 
concentration of surface-coupled ATRP initiators (the porous polycaprolactone (PPCL)-Br 
surfaces) via the reaction between hydroxyl groups on the PPCL films (prepared by using 
PEG as the pore-forming agent) and 2-bromoisobutyryl bromide for the subsequent surface 
initiated ATRP of NIPAAm [91]. The resultant PNIPAAm-grafted PPCL films possessed an 
interconnected porous structure and exhibited a low LCST of about 32°C. The potential of 
this grafted polymer film as controlled protein delivery system was then demonstrated using 
BSA as a model protein.
Metal nanoparticles are capable of absorbing energy and generate heat in response to radio 
frequency (RF), thus can also be utilized in the design and development of thermal-
responsive systems. Stanley and co-workers achieved remote regulation of in vivo insulin 
production by decorating a modified temperature-sensitive channel, TRPV1, with iron oxide 
nanoparticles (FeNPs) (Fig. 7) [92]. These FeNPs were coated with antibodies and heated in 
a low-frequency magnetic field, resulting in a temperature rise. Upon the rise of the local 
temperature, thermal-responsive TRPV1 was triggered to accelerate calcium transport and 
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increased insulin gene expression, leading to the synthesis and release of bioengineered 
insulin.
3.2. Light
Among all the stimuli utilized as controlled drug release triggers, light is especially 
attractive, as it can remotely trigger drug release with extremely high spatial and temporal 
precision with an on/off switching pulsatile manner [93, 94]. Additionally, in light-triggered 
delivery systems, release profiles can be regulated via the adjustment of a broad range of 
parameters, such as wavelength, light intensity, duration of exposure and beam diameter 
[95].
TiO2 nanomaterials have superior photocatalytic properties and show excellent 
biocompatibility, therefore, are considered as suitable nanocarriers for light-triggered protein 
delivery [96, 97]. Song et al. reported fabrication of an amphiphilic TiO2 nanotubular-
structured carrier for protein delivery. The controlled delivery aim was achieved via a 
hydrophobic cap on the hydrophilic TiO2 nanotube (Fig. 8) [98]. The loading and release 
efficacy of this delivery system were investigated and demonstrated using horseradish 
peroxidase (HRP) as model payload. The hydrophobic cap mentioned above prevented 
uncontrolled leakage of the hydrophilic protein cargo into aqueous environment, and it could 
then be removed upon exposure to UV signal via exploiting the photocatalytic nature of 
TiO2 for UV induced chain scission of attached organic monolayers [99], leading to UV-
triggered controlled release of protein cargoes. It is yet noteworthy that most proteins such 
as BSA were not endurable to UV irradiation [100]. Residues such as tryptophan, tyrosine, 
phenylalanine, and cysteine/cysteine will undergo photoinduced oxidation, thus are the 
primary targets of photodegradation in proteins. [101] Photooxidation has been recognized 
as the major contributor of protein degradation and can lead to changes in the primary, 
secondary, and tertiary structures of proteins. In a recent work, dendritic conjugates have 
been developed as fluorescent dendritic nanoprobes for an enhanced photostability. [102] 
Similar principles can be utilized to develop nanocarriers capable of protecting cargo 
proteins from photoinduced damages. Compared with UV, visible light is less harmful to 
proteins due to its lower energy. Luo and co-workers developed a visible light responsive 
protein delivery system assembled through coordinating hydroxyl onto TiO2 nanoparticle 
[103]. In their work, hemoglobin (Hb) was chosen as a model protein and covalent attached 
onto the surface of TiO2 nanoparticles utilizing the coordination of 3, 4-dihydroxyl benzoic 
acid (DB) to the unsaturated coordinative TiO2 ions. DB formed a charge-transfer complex 
with TiO2. Controlled release of Hb could then be achieved via cleavage of the coordination 
bonds between DB and TiO2 surfaces triggered by visible light. According to their 
investigation, the released Hb still maintained its structure and bio-catalytic activity.
Instead of directly delivering proteins, Schroeder and co-workers chose a different approach 
by delivering a “protein factory”, where the synthesis of proteins could be remotely 
triggered by UV (Fig. 9) [104]. This lipid based vesicle was filled with amino acids, 
ribosomes, and plasmid caged with a photolabile protecting group. Upon UV signal, the 
vesicle began to synthesize proteins with the cell free protein synthesis machinery. GFP and 
enzymatically active luciferase were produced using this method. In order to evaluate the 
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vesicle’s ability of protein production in vivo, the particles were injected locally into mice 
which were later treated with UV or kept untreated. Results of whole body bioluminescence 
imaging (Fig. 9-C) verified the nanoparticles’ capability of spatiotemporally producing 
active luciferase upon UV trigger.
Near-infrared light (NIR) has also been utilized to achieve controlled delivery. Tang et al. 
applied silica-coated gold nanorods onto the skin surface as NIR-responsive heat generator, 
in order to facilitate transdermal protein delivery [105]. NIR irradiations of the mouse skin 
using both a continuous-wave laser (CW-laser) and a pulsed laser were investigated, 
separately, using OVA as model protein. The researchers found that in the case of CW-laser, 
skin temperature rose upon irradiation, causing migration of inflammation cells and induced 
expression of heat shock protein (HSP70). Pulsed laser, on the other hand, didn’t increase 
skin temperature since the heated area was limited to the stratum corneum, thus skin 
histology remained unchanged and no HSP70 induction was observed. In both cases, the 
permeability of protein through the stratum corneum was enhanced due to the photothermal 
effect of gold nanorods, therefore providing an alternative approach for transdermal protein 
delivery and vaccination.
3.3. Electric field
Electric current has also been utilized to trigger protein/peptide release. There are basically 
two methods to develop electro-stimulated drug delivery systems.
One approach is to synthesize a pH-sensitive polymer and change the local pH via 
regulating the presence or absence of an electric current [106]. Electro stimulus is an indirect 
trigger, and this electro-responsive drug delivery system is essentially one derivative of pH-
responsive delivery systems. A typical class of materials with this kind of indirect electric-
sensitivity is complex of poly(ethyloxazoline) (PEOx) and poly(methacrylic acid) (PMAA) 
formed via hydrogen bonding between oxazoline group and carboxylic group. When pH is 
below 5.0, PEOx and PMAA form complex and precipitate immediately, while this solid-
state complex will dissolve instantly when pH is above 5.4 [107]. Kwon et al. investigated 
the phase change of PEOx/PMMA complex towards electric current trigger by attaching the 
PEOx/PMMA matrix onto platinum cathode. When an electric current was applied, the 
matrix surface facing the cathode began to dissolve as a result of the increased local pH.
The other way is the transportation of counterions and water molecules in the non-
degradable polymer matrix. Relevant electro-responsive hydrogels have long been studied. 
Back in 1995, Florence et al. reported the electro-responsive behavior of crosslinked 
hyaluronic acid (HA) [108]. HA is a naturally existing polysaccharide distributed widely 
throughout connective, epithelial, and neural tissues, which plays a central role in regulating 
cell growth and renewal. The system they developed showed a pulsatile release of model 
macromolecules: the hydrogel swelled upon switching off electric field, leading to release of 
the model macromolecule, and such a release behavior stopped immediately after the 
reapplication of the electric field. Shim and co-workers prepared semi- and full-
interpenetrating polymer network (IPN) hydrogels composed of poly(vinyl alcohol) and 
polyethyleneimine and investigated their bending behavior upon electro stimulus [109]. 
Semi-IPN referred to the IPN where one component of the assembly was crosslinked and the 
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other maintained its linear form, and full-IPN referred to the IPN where all polymer chains 
were crosslinked. The swelling behaviors showed that the swelling ratio of the semi-IPN 
hydrogels increased with PEI content in the matrix, while that of full-IPN hydrogels 
displayed a significant decrease by increasing PEI contents. In the water state of the 
hydrogels, the full-IPN hydrogels contain less free water in comparison with the semi-IPN 
hydrogels. Murdan et al. investigated the potential of chondroitin 4-sulphate (CS) hydrogels 
as electro-controlled carrier to delivery protein and peptide [110]. They studied the loading 
efficiency and release profiles of a CS hydrogel crosslinked with ethylene glycol diglycidyl 
ether, using three positively charged molecules (vasopressin, aprotinin and lysozyme) and 
one negatively charged protein (BSA) as model cargo. According to their study, the CS 
hydrogel displayed the capability to concentrate positively charged compounds while failed 
to concentrate negatively charged compounds effectively. Also, the loading efficiency 
increased with the decrease of the molecular size of the cargo molecules. The release of 
cargoes could be regulated by changing voltage, and protein was not released in the absence 
of an electrical field, which indicated the potential of this CS hydrogel as electro-responsive 
protein delivery platform.
3.4. Magnetic force
Magnetically guided delivery strategies have great potential in enhancing the therapeutic 
profile of drugs by increasing their distribution to the target site as well as lowering off-
target interactions. Magnetic targeting is based on two primary elements: a magnetic field 
source and a magnetically responsive drug carrier [111].
Magnetic nanoparticles are capable of targeting specific sites to kill tumors under the 
guidance of a magnetic field. Thus, designing nanovehicles based on magnetic nanoparticles 
is a rather appealing approach in designing controlled protein delivery systems. In order to 
determine whether mesoporous magnetic hollow nanoparticles (MMHs) can penetrate cell 
membranes and deliver protein into subcellular compartments, Huang et al. prepared 
different functionalized MMHs and investigated their intracellular trafficking using BSA as 
a model protein payload [112]. The MMHs were prepared adopting a reported facile three-
step procedure, where negatively charged polystyrene (PS) nanospheres were used as 
templates and then removed to form the hollow structure [113]. The results indicated that 
MMHs modified with amino groups (AMMHs) were efficient in protein loading and capable 
of transporting BSA into the cells and releasing the protein cargo into subcellular 
compartments, such as cytosol and nucleus. In addition, studies showed that the 
nanoparticles were biocompatible, and the encapsulated BSA maintained its bioactivity. 
Chorny and co-workers developed a magnetic force triggered protein delivery system based 
on magnetically responsive nanoparticles (MNP) prepared via the precipitation of calcium 
oleate in the presence of magnetite-based ferrofluid [114]. This system displayed great 
efficiency in the encapsulation of antioxidant enzymes, superoxide dismutase (SOD) and 
catalase, and also a considerable therapeutic effect via combating a severe oxidative insult in 
vitro under the guidance of magnetic field. Quantitative assay of cell uptake verified a 
71±4% internalization ratio of MNP (1 μg/well) after being treated with magnetic field for 4 
hours. The MNP’s capability of providing antioxidant protection was assayed by cell 
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viability study and demonstrated by the 62±12% recovery of HUVEC exposed to hydrogen 
peroxide at 10mM concentration for 5 hours.
Cho et al. developed a magnetic switch for the control of cell death signaling. In this work, 
death receptor 4 (DR4) monoclonal antibodies, which were highly expressed on tumour 
cells, were conjugated to magnetic nanoparticles via a specific antigen-antibody interaction 
(Fig. 10) [115]. They chose Zinc-doped iron oxide magnetic nanoparticles here for their high 
saturation magnetization value. When applying a magnetic field to aggregate magnetic 
nanoparticle conjugated DR4s, the magnetic switch is ‘ON’, thus promoting apoptosis 
signalling pathways. The efficacy of the magnetic switch for inducing apoptosis in vivo was 
evaluated using a zebrafish model. An approximately 3.5-fold morphological alteration in 
the tail region, which was a visible consequence of apoptosis signaling, confirmed the 
occurrence of apoptosis after applying a 0.50 T magnetic field for 24 hours.
3.5. Mechanical force
These years, controlled drug applying mechanical force as a trigger has attracted increasing 
interests. For example, Lee and co-workers developed alginate hydrogels to achieve 
pulsatile release of vascular endothelial growth factor (VEGF) in response to compressive 
forces with varying strain amplitudes [116]. Encapsulated cargo protein was released upon 
compression. And once the strain was removed, hydrogel resumed its initial volume.
Among all kinds of mechanical force, ultrasound has long been utilized in drug delivery area 
for its simplicity, security, inexpensiveness and real time applications [117]. Recently, Jin et 
al. reported a novel ultrasound-triggered insulin delivery system based on injectable 
polymeric nano-network (Fig. 11) [118]. PLGA was chosen as the matrix material and 
insulin loaded nano-network was prepared using a double emulsion method. Positively 
charged chitosan and negatively charged alginate were used as surfactants, respectively, in 
order to prepare oppositely charged nanoparticles. A cohesive nano-network was then 
developed by mixing the above-mentioned two kinds of oppositely charged nanoparticles. 
The insulin released from the nano-network displayed a ultrasound-triggered pulsatile 
profile mainly attributed to cavitation induced by focused ultrasound system (FUS). To fully 
evaluate the efficacy of this smart insulin delivery system as an alternative diabetes therapy, 
the reaserchers further extended their investigation to in vivo studies using STZ-induced 
adult diabetic mice as animal model. FUS was applied to the injection site for 30 sec 2 days 
after nano-network injection, leading to a rapid decrease of blood glucose level. Similar FUS 
treatment performed on day 4, day 7 and day 10 indicated the potential of this FUS-triggered 
insulin delivery stragety for sustained long-term insluin delivery.
4. Dual and multi-stimuli responsive systems
One appealing strategy that has emerged recently is to fabricate systems with the ability to 
respond to dual and multiple stimuli, thereby assuring drug release under complex 
pathological conditions with fine tuned drug release profile to augment therapeutic efficacy 
[119, 120]. Considerable variety of nanomaterials responsive to dual and multi-stimuli, such 
as pH/temperature, pH/redox, pH/glucose, pH/enzyme, dual enzyme, pH/temperature/
glucose have been developed and studied [120]. Among all the dual and multi-stimuli 
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responsive nanomaterials, nanomaterial responsive to both pH and temperature signals is 
one of the most studied. Zhang et al. developed smart hydrogels composed of pH-sensitive 
poly (acrylic acid) (PAA) and temperature-sensitive hydroxypropylcellulose-g-acrylic acid 
(HPC-g-AA) as protein carriers [121]. With respect to pH responsiveness, hydrogels with 
higher HPC-g-AA content resulted in lower equilibrium swelling. Decrease of swelling ratio 
was observed in the as-prepared hydrogels with the increase of temperature, yet the change 
was not significant. Although temperature had little influence on the swelling of the 
hydrogels, it determined the optical transmittance of the hydrogels, which indicated that the 
HPC parts of hydrogel became hydrophobic when the temperature was above the lower 
critical solution temperature. In addition, the hydrophilicity of PAA increases with the 
increase of pH, resulting in a pH-dependent temperature-sensitivity. In vitro protein release 
experiment was carried out first in artificial gastric juice (pH = 1.2) for 2 h and then in 
artificial intestinal liquid (pH = 6.8) for the subsequent 6 h, using BSA as a model protein. 
The release profiles showed that both HPC-g-AA and AA contents played important roles in 
the protein cargo release behaviors.
Wang and co-workers reported a triple-responsive protein delivery system prepared via the 
copolymerization of pH and temperature-sensitive (2-dimethylamino) ethyl methacrylate 
(DMAEMA) with glucose-sensitive 3-acrylamidephenylboronic acid (AAPBA) [122]. BSA 
was selected as a model protein to study the release profiles. The pH, temperature and 
glucose sensitivities were studied, respectively, and the effect of AAPBA content on the 
swelling ratio was also investigated. Based on the results of the mentioned studies, it was 
established that the swelling and protein release behavior of the ‘smart’ hydrogels were 
significantly influenced by both pH/temperature and glucose concentration at physiological 
pH.
Gu and co-workers incorporated photolabile caged peptide sequences into an enzymatically 
degradable polymeric nanocapsule and achieved controlled protein release triggered by 
enzyme and light (Fig. 12) [123]. This cocoon-like nanocapsule was prepared using a facile 
one-pot procedure (Fig. 12-A): deposition of monomers and crosslinkers onto the surface of 
cargo protein through physical adsorption including electrostatic force and van der Waals 
force followed by formation of polymeric protective shell via in situ free-radical 
polymerization facilitated by protease-cleavable bisacrolylated short peptide crosslinkers. 
The peptide crosslinkers began to proteolyze upon exposure to proteases, leading to the 
enzyme-triggered release of cargo protein. The degradability of the polymeric shell can be 
controlled by choosing the sequences of peptide crosslinker based on their sensitivity to 
different kinds of proteases, thus this study actually offered a general approach for the 
controlled protein delivery to different target sites. Photolabile caged peptide sequences 
were incorporated into the crosslinkers in order to achieve the spatiotemporally controlled 
release. In this study, the researchers selected CP3 as a model target protein to demonstrate 
the effectiveness of the nanocapsule for cytoplasmic delivery. A photolabile o-nitrobenzyl 
ester moiety (Dm) was conjugated onto the VDEVDTK peptide cross-linker in order to cage 
the P1 aspartic acid (Fig. 12-D). Upon exposure to UV, Dm was cleaved and exposed P1 
aspartic acid, the uncaged peptide cross-linker could then be cleaved by CP3, leading to the 
dissociation of the polymeric shell. Thus, the dissociation of the polymeric shell and release 
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of cargo protein could only be achieved via synergistic effect of UV irradiation and CP3 
hydrolysis.
Dual- and multi-responsive nanomaterials capable of targeting complex physiological 
environment hold great potential in further fine tuning the delivery precision and enhancing 
the therapeutic efficacy of released proteins and peptides, thence have been aggressively 
pursued these years. However, to date, these reported dual- and multi-responsive systems are 
often proof-of principle studies due to difficulty in validating sequential or synergistic 
effects in complicated in vivo environment. Systemic investigations need to be conducted 
and enormous efforts are required to be invested before these novel systems can finally be 
utilized in clinical practice.
5. Summary and outlook
As discussed above, nanomaterials sensitive to physiological or exogenous stimuli have 
been widely applied to delivery therapeutic proteins at the right time and (or) place. Dual 
and multi-responsive nanomaterials sensitive to combinations of triggers in order to 
customize more specific delivery have also been developed. Relevant materials can be 
flexibly assembled into diverse formulations to achieve enhanced efficacy. Table 1 
summarizes typical examples of different stimuli-responsive nanosystems reported recently.
Despite remarkable achievements in this field, systems tested in in vivo preclinical models 
or stepped into the clinical stage remain elusive [124]. There are still several challenges that 
hamper their translation from the bench to the bedside and need to be essentially addressed. 
First of all, in order to fully achieve clinical potential, the relationship between precise 
release of protein cargoes at the exact “responsive” site (location/time) and 
pharmacokinetics should be coordinated [125]. For example, an effective and efficient 
intracellular protein delivery tool should make sure the nanocarriers have sufficient period 
of time to be activated to release cargoes through cellular environmental elements, such as 
acidic or redox potential. Additionally, for glucose-responsive insulin delivery systems, one 
challenging issue is to achieve fast response to mimic the function of healthy pancreatic 
cells [67]. Relevant parameters associated with materials, formulations and target proteins 
can be further tailored to meet the criteria. Second, the translation is limited by the 
complexity of formulation design and obstacles in scaling-up of synthesis. Formulations 
with compromise of a simple but effective architectural design are highly possible to win the 
chance for clinic. Third, how to achieve sufficient biocompatibility is an intractable issue to 
be solved. One emerging research theme includes engineering nanomaterials that 1) can 
highly avoid biological sequestration for reducing immune toxicity; 2) have good 
biodegradability to eventually eliminate through renal clearance for reducing long-term or 
whole-body toxicity [126]. Lastly, issues related to the tissue penetration depth and side 
effects of the exogenous physical stimulus would also need to be solved. Meanwhile, 
exploring new stimuli, for example, those are closely associated with metabolic levels and 
have targeting efficacy, can also be highly desirable [127].
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Schematic of “Magic Cube” for protein delivery: combination of a variety of triggering 
mechanisms and carrier formulations for delivery of a broad spectrum of functional proteins.
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(A) Schematic illustration of the synthesis and cellular uptake of cationic single-protein 
nanocapsules with degradable and non-degradable polymeric shells. (B) (i)(ii) TEM (i) and 
AFM (ii) images of the HRP nanocapsules; (iii) TEM image of nanocapsules with a gold-
quantum-dot-labelled HRP core for demonstration of the nanocapsule architecture. (C) 
Particle sizes of degradable and non-degradable nanocapsules at pH 5.5 (i) and pH 7.4 (ii). 
(D) Fluorescence intensity of native EGFP, non-degradable EGFP nanocapsules (nEGFP) 
and degradable EGFP nanocapsules (de-nEGFP) after exposure to 1 mg·L−1 trypsin and α-
chymostrypsin in buffer (pH 7.4, 50 °C). (E) Fluorescence intensity of HeLa cells incubated 
with nEGFP or de-nEGFP for 3 h followed by incubation in fresh media. Adapted with 
permission from Ref. [34].
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Redox-responsive polymeric nanocapsule for intracellular delivery of tumor-selective 
apoptin complex: (A) Schematic illustration of degradable apoptin nanocapsules (S-S APO 
NC) synthesis (upper) and intracellular delivery to induce apoptosis of tumor cells (lower). 
(B) TEM image of S-S APO NC. (C) Tumor inhibition observed in mice treated by S-S 
APO NC. Adapted with permission from Ref. [50].
Lu et al. Page 29























(A) Scheme of TRAIL and Dox co-loaded Gelipo (TRAIL/Dox-Gelipo) for sequential and 
site-specific drug delivery. (B) TEM image of TRAIL/Dox-Gelipo, scale bar: 200 nm. (C) 
MDA-MB-231 tumor growth curves after intravenous injection of different formulations. 
Adapted with permission from Ref. [64].
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(A) Schematic illustration of injectable nano-network for glucose-responsive insulin 
delivery. (B) SEM image of formed nano-network. (C) In vitro accumulated insulin release 
from nano-network under different glucose concentrations. (D) In vivo studies of the nano-
network for type 1 diabetes therapy: blood glucose levels (i) and plasma human insulin 
concentration (ii) in type 1 diabetic mice injected with 1×PBS, insulin and enzyme 
encapsulated nano-network, insulin encapsulated nano-network, enzyme encapsulated nano-
network, and insulin solution. Adapted with permission from Ref. [70].
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MSN-based glucose-responsive system for co-delivery of insulin and cyclic AMP: (A) 
Schematic illustration of the glucose-responsive co-delivery system; (B) TEM images of 
boronic acid-functionalized MSN (i) and FITC-G-Ins-capped MSN (ii). Adapted with 
permission from Ref. [82].
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Iron oxide nanoparticle based plasma glucose regulation triggered by radio-wave heating: 
(A) Schematic illustration of cell activation and gene expression induced by iron oxide 
nanoparticle. (B) Effects of RF treatment on blood glucose (i) and plasma insulin (ii) in PBS 
and nanoparticle-treated mice with tumors expressing TRPV1His and calcium-dependent 
human insulin. Adapted with permission from Ref. [92].
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UV-responsive amphiphilic TiO2 nanotube arrays for controlled drug delivery: (A) Scheme 
of amphiphilic TiO2 nanotube layer fabrication. (B) Four methods for HRP loading. (C) 
Schematic illustration of HRP release under UV illumination. (D) Relative intensity of 
reflected light over time of HRP loaded TiO2 nanotubes after exposure to PBS without 
illumination (a), 50% UV illumination (b), and full UV illumination (c). Curve d shows the 
release of HRP from TiO2 nanotubes without surface modification. Adapted with permission 
from Ref. [98].
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Light-triggered protein-producing nanoparticle: (A) Scheme of lipid vesicles encapsulated 
with cellular machinery responsible for transcription and translation. (B) Overlaid 
transmitted light and fluorescence images of a GFP-producing particle. (C) Production of 
luciferase in vivo induced by UV irradiation: (i) bioluminescence imaging of mice injected 
locally with protein-producing nanoparticles; (ii) quantitation of the bioluminescence 
imaging shown in (i). Adapted with permission from Ref. [104].
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(A) Schematic illustration of magnetic switch for apoptosis signaling in vitro and in vivo; 
(B) (i) magnetic switch set-up for apoptosis signaling; (ii)(iii) confocal microscope (ii) and 
SEM (iii) images of Ab–MNP (1 pM)-treated DLD-1 cells; (iv) biomimetic magnetic switch 
for apoptosis signaling induction via receptor aggregation. Adapted with permission from 
Ref. [115].
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(A) Schematic illustration of FUS-mediated insulin delivery: (i) FUS triggered insulin 
release from nano-network; (ii) noninvasive long-term blood glucose regulation controlled 
by FUS. (B) FUS-mediated in vivo blood glucose regulation: (i) schematic illustration of 
experimental apparatus; (ii) blood glucose levels in STZ-induced C57B6 diabetic mice with 
and w/o FUS treatment: FUS treatment was repeatedly applied three times and the 
administration windows are represented by the blue solid columns. Adapted with permission 
from Ref. [118].
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(A) Scheme of protein nanocapsule preparation via in situ free-radical polymerization. (B) 
Typical monomers and cross-linker used in this study. (C) TEM images of fresh CP3 
nanocapsules (i) and CP3 nanocapsules after self-degradation (ii). (D) Schematic illustration 
of the structure and function of the peptide cross-linker CL-VDEVDmTK. Adapted with 
permission from Ref. [123]
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Table 1





Physiological pH PIC micelles CytC, IgG Intracellular: HuH-7 [28,
29]
PP-75 MBP-Apoptin Intracellular: Saos-2 [128]
cross-linked PDEAEMA-core/
PAEMA-shell particles
OVA protein Intracellular: CD8+
T-cells
[32]
TMC-based PEC nanocarriers R-GAL Intracellular [33]
polyaspartamide nanocapsules BSA Intracellular: NIH-3T3 [14]









Arginase, GFP Intracellular: HepG2,
HeLa and L929
[38]
PAAD/PGA hydrogels insulin Serum [43]
multi-ion-crosslinked NPs insulin Serum [44]
PLA-PEG NP insulin Serum [45]
Redox single-protein nanocapsules CP3 Intracellular: HeLa,
MCF-7 and U-87 MG
[49]






insulin Intracellular: A549 [51]




cell lines, HeLa and
MEF
[54]
protein nanocapsules BSA, VEGF Intracellular:
HUVECs
[56]
PEG hydrogels BSA, lysozyme [61]












ConA contained hydrogels insulin [77]































BA-MSN insulin Serum [82]
External
Temperature chitosan-PEG copolymer based
hydrogels
BSA [88]
PNIPAAm hydrogels insulin, BSA [90]
PNIPAAm-grafted PPCL films BSA [91]





TiO2 nanoparticles Hb [103]
lipid based nanoparticles GFP, luciferase Serum [104]
silica-coated gold nanorods OVA Skin [105]






Magnetic force AMMHs BSA Intracellular: A375 [112]






Ab-MNPs DR4 Intracellular: DLD-1 [115]
Mechanical
force
calcium alginate hydrogels VEGF [116]
PLGA nano-network insulin Serum [117]
Dual and
Multi-stimuli






Enzyme/light polymeric nanocapsules CP3 Intracellular: Hela [123]
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